-

10:00:48 AM

OCUL Stock News

OCUL - Ocular Therapeutix Inc

10/22/21 8:00 AM

Nasdaq : OCUL

clinical trial

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from its Phase 2 clinical trial of OTX-CSI for the treatment of dry eye disease. The Phase 2, U.S.- based, randomized, double-masked, multi-center,...

RHEA-AI

neutral

10/11/21 12:30 PM

Nasdaq : OCUL

fda approval

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S. Food and Drug Administration has approved its Supplemental New Drug Application to broaden the DEXTENZA label to add an additional indication for the...

RHEA-AI

very positive

09/28/21 8:00 AM

Nasdaq : OCUL

management

Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations. “We are excited to welcome Karen-Leigh to the Ocular team,” said Antony...

RHEA-AI

neutral

09/13/21 6:45 AM

Nasdaq : OCUL

Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market unit sales of DEXTENZA ® billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the Company’ s corporate presentation at the...

RHEA-AI

neutral

09/07/21 8:00 AM

Nasdaq : OCUL

conferences

Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact...

RHEA-AI

neutral

08/10/21 8:00 AM

Nasdaq : OCUL

conferences

Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate in two panels and will provide a pre-recorded presentation at

RHEA-AI

neutral

08/09/21 4:01 PM

Nasdaq : OCUL

earnings

Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the second quarter of 2021, and provided updates on its

RHEA-AI

neutral

08/05/21 4:01 PM

Nasdaq : OCUL

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Regeneron has terminated the option and license agreement collaboration between the

RHEA-AI

positive

07/29/21 8:00 AM

Nasdaq : OCUL

clinical trial

Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patient in the United States Phase 1 clinical trial of

RHEA-AI

neutral

07/28/21 8:00 AM

Nasdaq : OCUL

conferencesearnings

Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter financial results on Monday, August 9, 2021.

RHEA-AI

neutral

OCUL Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ocutx.com
CeoAntony Mattessich
Security nameOcular Therapeutix Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees181
Tags
- Health Technology
- Pharmaceuticals: Other
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address24 Crosby Dr
StateMassachusetts
CityBedford
Zip01730-1402
CountryUS
Phone17818953235

OCUL Description:

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.